Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $454.82M
• Dividend Yield: N/A
• Average Volume (3M): 208.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -71.42%
• EPS Growth: -248.91%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 38,284,313
• 10 Day Avg. Volume: 255,124
• 30 Day Avg. Volume: 208,723
• PEG Ratio: <0.01
• Price to Book (P/B): 1.39
• Price to Sales (P/S): 16.73
• P/FCF Ratio: -3.28
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 16.34
• Enterprise Value/Gross Profit: -30.04
• Enterprise Value/Ebitda: -2.75
• 1Y Price Target: $20.00
• Price Target Upside: 58.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -3.87
• Revenue Forecast (FY): $24.99M

• Rating: 55 Neutral
• Price Target: $13.00 ▲(3.26% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is held back primarily by weak and volatile financial performance, particularly the sharp 2025 reversal into large losses and heavy cash burn. Offsetting this, technicals indicate an improving trend with supportive momentum, and corporate updates provide positive pipeline and regulatory progress plus a stated runway into Q3 2027. Valuation remains only middling because a negative P/E reflects ongoing losses and there is no dividend support.

Positive Factors

Pipeline advancement & regulatory designations

Multiple RNA programs moving through clinical milestones and an FDA Rare Pediatric Disease Designation materially de-risks specific assets and validates development capability. Durable pipeline progress supports future milestone payments, broadened indication reach and sustained partner interest over the next 2–6 months and beyond.

Proprietary intracellular delivery platform

A differentiated intracellular delivery technology provides a structural competitive advantage by enabling therapeutics across multiple modalities and indications. Platform-based R&D increases leverage from each scientific advance, supports multiple candidate programs, and enhances partnership and licensing opportunities over the medium term.

Manageable leverage with reported runway

Relatively low debt and a sizable equity base, alongside management's reported cash runway into Q3 2027, provide meaningful operational flexibility. This structural financial buffer reduces near-term refinancing pressure and supports continued execution of clinical programs over the next several quarters.

Negative Factors

High and worsening cash burn

Sharp deterioration in operating and free cash flow creates a persistent funding need that can force dilutive capital raises or constrain R&D pacing. Sustained negative cash generation undermines financial resilience and raises execution risk if clinical programs require additional investment before value‑creating inflection points.

Revenue volatility and 2025 collapse

A dramatic year‑over‑year revenue decline and switch from prior profitability signal lumpy, nonrecurring income likely tied to milestone timing or one‑offs. This volatile top‑line history weakens predictability of cash flows and margins, complicating planning and increasing reliance on external funding until steady commercial revenues emerge.

Dependence on partnerships and external financing

Business model reliant on collaborations, milestone payments and equity financings produces lumpy, milestone‑driven revenue and recurring dilution risk. Until the company achieves sustainable commercial sales, dependence on partners and capital markets constrains long‑term cash predictability and shareholder value retention.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Entrada Therapeutics generates revenue through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with pharmaceutical firms and research organizations to develop its therapies, often receiving milestone payments and royalties from these partnerships. Additionally, Entrada may receive funding from government and non-profit organizations aimed at supporting research in rare and genetic diseases. As the company advances its drug candidates through clinical trials, it may also attract further investments and partnerships, enhancing its revenue potential.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Financials are mixed but currently pressured: results swung from strong profitability in 2024 to a sharp 2025 revenue decline (~59%) and a large net loss ($143.8M). Cash flow is a key weakness with operating cash burn worsening in 2025 (-$128.5M) and deeply negative free cash flow (-$129.6M), despite a relatively manageable leverage profile and sizable equity base.

Income Statement

Results are highly volatile year-to-year. The company posted strong profitability in 2024 (about 31% net margin on $210.8M of revenue), but performance deteriorated sharply in 2025 with revenue down ~59% to $25.4M and a large net loss of $143.8M (deeply negative margin). Earlier years show mostly losses and periods of minimal revenue, which lowers confidence in earnings durability.

Balance Sheet

Leverage looks manageable: debt-to-equity remains low (roughly 0.14–0.17 in 2024–2025), and equity is still sizable at $306.1M in 2025. The main weakness is declining equity from 2024 to 2025 (down materially alongside losses) and a reduction in total assets, suggesting the balance sheet is being used to fund operating needs.

Cash Flow

Cash generation is inconsistent and recently negative. Operating cash flow swung from a strong inflow in 2023 ($139.8M) to outflows in 2024 (-$41.6M) and a much larger burn in 2025 (-$128.5M), with free cash flow also deeply negative in 2025 (-$129.6M). This pattern points to elevated funding risk if losses and cash burn persist.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	25.42M	210.78M	129.01M	0.00	0.00
Gross Profit	21.32M	210.78M	129.01M	0.00	0.00
EBITDA	-142.40M	47.01M	-321.00K	-95.35M	-50.01M
Net Income	-143.75M	65.63M	-6.68M	-94.62M	-51.16M
Balance Sheet
Total Assets	377.38M	526.32M	469.19M	252.06M	305.83M
Cash, Cash Equivalents and Short-Term Investments	295.70M	420.00M	351.97M	188.71M	291.06M
Total Debt	50.93M	59.21M	68.23M	25.94M	0.00
Total Liabilities	71.25M	97.64M	226.83M	39.50M	7.12M
Stockholders Equity	306.13M	428.68M	242.36M	212.55M	298.72M
Cash Flow
Free Cash Flow	-129.55M	-44.72M	134.19M	-96.67M	-55.44M
Operating Cash Flow	-128.51M	-41.56M	139.80M	-93.79M	-50.86M
Investing Cash Flow	116.81M	-27.80M	-138.40M	-148.65M	-4.58M
Financing Cash Flow	887.00K	102.96M	21.04M	479.00K	307.46M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Positive. The current price of 12.59 is above the 20-day moving average (MA) of 12.19, above the 50-day MA of 11.40, and above the 200-day MA of 8.26, indicating a bullish trend. The MACD of 0.46 indicates Negative momentum. The RSI at 55.58 is Neutral, neither overbought nor oversold. The STOCH value of 62.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRDA	55 Neutral	$454.82M	-2.96	-39.83%	―	-71.42%	-248.91%
BDTX	52 Neutral	$124.32M	―	16.78%	―	―	―
CCCC	52 Neutral	$262.49M	-1.51	-53.83%	―	-10.57%	1.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMT	50 Neutral	$150.67M	-3.75	-40.85%	―	―	-38.23%

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics highlights RNA pipeline progress and outlook

On January 8, 2026, Entrada Therapeutics reported significant 2025–early 2026 progress across its RNA-based pipeline for neuromuscular and ocular diseases, including completion of Cohort 1 dosing in the global Phase 1/2 MAD ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy (DMD), transition to the open-label Phase 2 portion, and receipt of Rare Pediatric Disease Designation from the U.S. FDA in December 2025. The company has initiated dosing in the Phase 1/2 MAD ELEVATE-45-201 trial of ENTR-601-45, secured U.K. authorization to start a Phase 1/2 MAD study of ENTR-601-50 in DMD patients amenable to exon 50 skipping, plans regulatory filings for ENTR-601-51 in 2026, and continues to support Vertex’s ongoing global Phase 1/2 trial of VX-670 in myotonic dystrophy type 1, targeting completion of the MAD portion’s enrollment and dosing in the first half of 2026. Entrada also expanded into ophthalmology by selecting ENTR-801 in December 2025 as its first ocular clinical candidate for Usher syndrome type 2A, supported by robust preclinical data, and indicated that around 15,000 US and European patients may be addressable by exon 13 skipping; coupled with a reported cash runway into the third quarter of 2027 and a high-profile investor presentation scheduled for January 14, 2026 at the J.P. Morgan Healthcare Conference, these developments underscore the company’s intent to solidify its position as a leading player in RNA-based therapies for high-unmet-need genetic diseases.

The most recent analyst rating on (TRDA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.